Understanding MPXPS: MICU1-Related Myopathy

Finding out that your child has MPXPS (Myopathy with Extrapyramidal Signs), specifically the form caused by variants in the MICU1 gene, can be an isolating and overwhelming experience. Because this condition is exceptionally rare, you may find that your local doctors, and even some specialists, have never treated a patient with it before ^[1][2].

The “diagnostic odyssey”—the long period of time spent searching for an answer while undergoing various tests—is a common experience for families of children with rare genetic conditions ^[3]. You may have been told your child had a different type of muscular dystrophy or a general developmental delay before the MICU1 variant was finally identified.

What is MICU1-Related MPXPS?

At its core, this is a mitochondrial disorder. Mitochondria are the “power plants” of your cells, and they rely on calcium to function correctly ^[4]. The MICU1 gene provides the instructions for a protein that acts as a regulatory component, or “gatekeeper,” for calcium entering the mitochondria ^[1].

When this gatekeeper is missing or doesn’t work (due to a loss-of-function variant), the mitochondria cannot properly regulate how much calcium they take in. Based on experimental models, researchers believe this leads to several issues:

• Energy Production: The mitochondria may struggle to efficiently make ATP (the primary energy source for cells) ^[1].
• Cell Stress: Mishandled calcium has been observed to lead to the production of reactive oxygen species (harmful molecules) that can cause cell stress or injury ^[5].
• Muscle and Brain Impact: Because muscles and the brain require massive amounts of energy, they are the parts of the body most commonly affected by this process ^[6][4].

Genetics and Inheritance

MPXPS is inherited in an autosomal recessive manner. This means a child must inherit a non-working copy of the gene from both parents to be affected ^[7]. Usually, both parents are healthy “carriers” of one working and one non-working gene. When both parents are carriers, there is a 25% chance with each pregnancy of having an affected child. A genetic counselor can help you understand these risks and discuss testing options for siblings or other family members.

A Condition of Rarity and Variability

While the exact number of people with this condition worldwide is unknown, medical literature consists mostly of small case series and reports ^[1][2]. One of the most important things for families to understand is that the name “Myopathy with Extrapyramidal Signs” can be slightly misleading. The features do not look the same in every child:

• Myopathy (Muscle Disease): A primary feature is muscle weakness and fatigability (tiring very easily) ^[1]. The median age when symptoms first appear is around 3 years old, though a diagnosis often comes much later ^[6]. A key lab finding is a persistently elevated level of creatine kinase (CK), an enzyme that leaks into the blood when muscle is stressed ^[1][7].
• Movement Differences: Extrapyramidal signs refer to movement issues like chorea (jerky, involuntary movements) or dystonia (abnormal postures). Crucially, about half of the patients documented in research do NOT have these signs ^[8][2]. Some children may only have muscle weakness and learning differences.

What Research Knows—and What It Doesn’t

Because there are so few known cases, researchers are still working to answer many questions.

What is well-established:

• The Cause: We know the condition is caused by biallelic (two) variants in the MICU1 gene that disrupt mitochondrial calcium regulation ^[1][4].
• The Signature: Persistently high CK levels and childhood-onset weakness are the most common clues that lead to genetic testing ^[6][1].

What remains uncertain:

• Long-Term Outlook: There are no established “survival curves” or clear predictions for how the disease progresses over decades. The long-term course remains uncertain for any individual child, and follow-up data in the literature is limited ^[8][7].
• Episodic Weakness: A small number of individuals have been reported to experience severe, sudden episodes of muscle weakness that last for hours or days, but this is not yet a formally established subtype of the disease ^[8].

Managing the Condition

There is currently no cure for MPXPS, but care focuses on managing symptoms and supporting development. This often includes physical, occupational, and speech therapy to help children maintain strength and communication skills ^[9]. Your child’s care team will likely include a neurologist and a geneticist. Together, they can help you navigate the specific ways MPXPS affects your child and build an individualized plan.